HUE040548T2 - Onkosztatin-M-receptor antigénjét kötõ fehérjék - Google Patents

Onkosztatin-M-receptor antigénjét kötõ fehérjék

Info

Publication number: HUE040548T2
Authority: HU; Hungary
Prior art keywords: oncostatin; antigen binding; binding proteins; receptor antigen; receptor
Prior art date: 2013-05-30

Application number

HUE14734671A

Other languages

English (en)

Inventor

Heather A Arnett

Sabine S Escobar

Chadwick T King

Ai Ching Lim

Saravanakumar Narayanan

Paul H Weinreb

Nels E Pederson

Original Assignee

Kiniksa Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-30

Filing date

2014-05-30

Publication date

2019-03-28

2014-05-30 Application filed by Kiniksa Pharmaceuticals Ltd filed Critical Kiniksa Pharmaceuticals Ltd

2019-03-28 Publication of HUE040548T2 publication Critical patent/HUE040548T2/hu

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

HUE14734671A 2013-05-30 2014-05-30 Onkosztatin-M-receptor antigénjét kötõ fehérjék HUE040548T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361829082P	2013-05-30	2013-05-30

Publications (1)

Publication Number	Publication Date
HUE040548T2 true HUE040548T2 (hu)	2019-03-28

Family

ID=51059621

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE18185359A HUE056580T2 (hu)	2013-05-30	2014-05-30	Onkosztatin-M-receptor antigénjét kötõ fehérjék
HUE14734671A HUE040548T2 (hu)	2013-05-30	2014-05-30	Onkosztatin-M-receptor antigénjét kötõ fehérjék

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HUE18185359A HUE056580T2 (hu)	2013-05-30	2014-05-30	Onkosztatin-M-receptor antigénjét kötõ fehérjék

Country Status (23)

Country	Link
US (6)	US9663571B2 (hu)
EP (4)	EP3456743B1 (hu)
JP (4)	JP6243521B2 (hu)
KR (3)	KR101882366B1 (hu)
CN (3)	CN105555803B (hu)
AU (4)	AU2014273966B2 (hu)
BR (1)	BR112015029643B1 (hu)
CA (1)	CA2910732A1 (hu)
DK (2)	DK3456743T3 (hu)
EA (1)	EA201592285A1 (hu)
ES (2)	ES2692657T3 (hu)
HK (3)	HK1221961A1 (hu)
HU (2)	HUE056580T2 (hu)
IL (2)	IL267382B (hu)
MX (2)	MX351127B (hu)
NZ (2)	NZ753995A (hu)
PL (2)	PL3456743T3 (hu)
PT (2)	PT3456743T (hu)
SG (1)	SG11201508829QA (hu)
SI (2)	SI3004167T1 (hu)
TR (1)	TR201815608T4 (hu)
WO (1)	WO2014194274A2 (hu)
ZA (1)	ZA201508064B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9663571B2 (en)	2013-05-30	2017-05-30	Kiniksa Pharmaceuticals, Ltd.	Oncostatin M receptor antigen binding proteins
WO2016120625A1 (en) *	2015-01-29	2016-08-04	Isis Innovation Limited	Biomarker
US10093731B2 (en)	2017-02-24	2018-10-09	Kindred Biosciences, Inc.	Anti-IL31 antibodies for veterinary use
MA53466A (fr) *	2017-04-11	2021-09-08	Kiniksa Pharmaceuticals Ltd	Formulation stable d'anticorps anti-osmr
CA3073537A1 (en) *	2017-08-22	2019-02-28	Sanabio, Llc	Soluble interferon receptors and uses thereof
WO2019229525A2 (en) *	2018-04-25	2019-12-05	Kiniksa Pharmaceuticals, Ltd.	TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRβ ANTIBODY
WO2020036833A1 (en) *	2018-08-13	2020-02-20	Kiniksa Pharmaceuticals, Ltd.	Treatment of skin diseases or disorders by delivery of anti-osmrbeta antibody
WO2020097252A1 (en) *	2018-11-06	2020-05-14	University Of Miami	Compositions and production of recombinant aav viral vectors capable of glycoengineering in vivo
CN110563844A (zh) *	2019-09-04	2019-12-13	华中农业大学	一种抗犬白介素31受体的多克隆抗体及其应用
TW202221039A (zh) *	2020-10-19	2022-06-01	美商碩騰服務公司	犬及貓抑瘤素Ｍ受體β之抗體及其用途
KR20240049286A (ko) *	2021-07-30	2024-04-16	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	Osmr-특이적 모노클로날 항체 및 이의 사용 방법
WO2024002259A1 (zh) *	2022-06-29	2024-01-04	百奥赛图(北京)医药科技股份有限公司	一种osm、osmr、il31ra和/或il31基因修饰的非人动物

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US233A (en)		1837-06-14		Improvement in plows
US4447A (en)		1846-04-04		Car- wheel
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US3691016A (en)	1970-04-17	1972-09-12	Monsanto Co	Process for the preparation of insoluble enzymes
CA1023287A (en)	1972-12-08	1977-12-27	Boehringer Mannheim G.M.B.H.	Process for the preparation of carrier-bound proteins
US3896111A (en)	1973-02-20	1975-07-22	Research Corp	Ansa macrolides
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4195128A (en)	1976-05-03	1980-03-25	Bayer Aktiengesellschaft	Polymeric carrier bound ligands
US4330440A (en)	1977-02-08	1982-05-18	Development Finance Corporation Of New Zealand	Activated matrix and method of activation
CA1093991A (en)	1977-02-17	1981-01-20	Hideo Hirohara	Enzyme immobilization with pullulan gel
US4151042A (en)	1977-03-31	1979-04-24	Takeda Chemical Industries, Ltd.	Method for producing maytansinol and its derivatives
US4137230A (en)	1977-11-14	1979-01-30	Takeda Chemical Industries, Ltd.	Method for the production of maytansinoids
US4229537A (en)	1978-02-09	1980-10-21	New York University	Preparation of trichloro-s-triazine activated supports for coupling ligands
US4265814A (en)	1978-03-24	1981-05-05	Takeda Chemical Industries	Matansinol 3-n-hexadecanoate
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4307016A (en)	1978-03-24	1981-12-22	Takeda Chemical Industries, Ltd.	Demethyl maytansinoids
JPS5562090A (en)	1978-10-27	1980-05-10	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
US4256746A (en)	1978-11-14	1981-03-17	Takeda Chemical Industries	Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en)	1978-11-14	1980-05-20	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS55164687A (en)	1979-06-11	1980-12-22	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS55102583A (en)	1979-01-31	1980-08-05	Takeda Chem Ind Ltd	20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en)	1979-06-05	1980-12-18	Takeda Chem Ind Ltd	Antibiotic c-15003pnd and its preparation
JPS55164685A (en)	1979-06-08	1980-12-22	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4309428A (en)	1979-07-30	1982-01-05	Takeda Chemical Industries, Ltd.	Maytansinoids
JPS5645483A (en)	1979-09-19	1981-04-25	Takeda Chem Ind Ltd	C-15003phm and its preparation
JPS5645485A (en)	1979-09-21	1981-04-25	Takeda Chem Ind Ltd	Production of c-15003pnd
EP0028683A1 (en)	1979-09-21	1981-05-20	Takeda Chemical Industries, Ltd.	Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en)	1980-10-08	1982-04-15	Takeda Chemical Industries Ltd	4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en)	1980-11-03	1984-05-22	Standard Oil Company	Impact improvement of high nitrile resins
US4315929A (en)	1981-01-27	1982-02-16	The United States Of America As Represented By The Secretary Of Agriculture	Method of controlling the European corn borer with trewiasine
US4313946A (en)	1981-01-27	1982-02-02	The United States Of America As Represented By The Secretary Of Agriculture	Chemotherapeutically active maytansinoids from Trewia nudiflora
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4475196A (en)	1981-03-06	1984-10-02	Zor Clair G	Instrument for locating faults in aircraft passenger reading light and attendant call control system
JPS57192389A (en)	1981-05-20	1982-11-26	Takeda Chem Ind Ltd	Novel maytansinoid
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
EP0088046B1 (de)	1982-02-17	1987-12-09	Ciba-Geigy Ag	Lipide in wässriger Phase
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4447224A (en)	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
US4487603A (en)	1982-11-26	1984-12-11	Cordis Corporation	Implantable microinfusion pump system
US4486194A (en)	1983-06-08	1984-12-04	James Ferrara	Therapeutic device for administering medicaments through the skin
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en)	1983-11-01	1988-11-17	Terumo Corp	Pharmaceutical composition containing urokinase
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
EP0206448B1 (en)	1985-06-19	1990-11-14	Ajinomoto Co., Inc.	Hemoglobin combined with a poly(alkylene oxide)
US5681930A (en)	1985-12-20	1997-10-28	Bristol-Myers Squibb Company	Anti-oncostatin M monoclonal antibodies
JPS63502716A (ja)	1986-03-07	1988-10-13	マサチューセッツ・インステチュート・オブ・テクノロジー	糖タンパク安定性の強化方法
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5011912A (en)	1986-12-19	1991-04-30	Immunex Corporation	Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US4965195A (en)	1987-10-26	1990-10-23	Immunex Corp.	Interleukin-7
US4968607A (en)	1987-11-25	1990-11-06	Immunex Corporation	Interleukin-1 receptors
WO1990005183A1 (en)	1988-10-31	1990-05-17	Immunex Corporation	Interleukin-4 receptors
WO1990005144A1 (en)	1988-11-11	1990-05-17	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US6291158B1 (en)	1989-05-16	2001-09-18	Scripps Research Institute	Method for tapping the immunological repertoire
US5683888A (en)	1989-07-22	1997-11-04	University Of Wales College Of Medicine	Modified bioluminescent proteins and their use
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
US5292658A (en)	1989-12-29	1994-03-08	University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center	Cloning and expressions of Renilla luciferase
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
ZA912136B (en) *	1990-03-29	1992-11-25	Bristol Myers Squibb Co	Anti-oncostatin m monoclonal antibodies
WO1991018982A1 (en)	1990-06-05	1991-12-12	Immunex Corporation	Type ii interleukin-1 receptors
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
CA2105984C (en)	1991-03-11	2002-11-26	Milton J. Cormier	Cloning and expression of renilla luciferase
US5262522A (en)	1991-11-22	1993-11-16	Immunex Corporation	Receptor for oncostatin M and leukemia inhibitory factor
ES2227512T3 (es)	1991-12-02	2005-04-01	Medical Research Council	Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0563475B1 (en)	1992-03-25	2000-05-31	Immunogen Inc	Cell binding agent conjugates of derivatives of CC-1065
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
US6239328B1 (en)	1992-10-05	2001-05-29	North Carolina State University	Method for reducing expression variability of transgenes in plant cells
CA2146559A1 (en)	1992-10-23	1994-05-11	Melanie K. Spriggs	Methods of preparing soluble, oligomeric proteins
AU690528B2 (en)	1992-12-04	1998-04-30	Medical Research Council	Multivalent and multispecific binding proteins, their manufacture and use
US5457035A (en)	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
DE69435112D1 (de)	1993-09-10	2008-08-21	Univ Columbia	Verwendung von grünem fluoreszenzprotein
WO1995021191A1 (en)	1994-02-04	1995-08-10	William Ward	Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5783672A (en)	1994-05-26	1998-07-21	Immunex Corporation	Receptor for oncostatin M
US5777079A (en)	1994-11-10	1998-07-07	The Regents Of The University Of California	Modified green fluorescent proteins
US5874304A (en)	1996-01-18	1999-02-23	University Of Florida Research Foundation, Inc.	Humanized green fluorescent protein genes and methods
US5804387A (en)	1996-02-01	1998-09-08	The Board Of Trustees Of The Leland Stanford Junior University	FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en)	1996-02-06	1999-03-02	Bryan; Bruce	Bioluminescent novelty items
US5925558A (en)	1996-07-16	1999-07-20	The Regents Of The University Of California	Assays for protein kinases using fluorescent protein substrates
US6037525A (en)	1996-08-01	2000-03-14	North Carolina State University	Method for reducing expression variability of transgenes in plant cells
US5976796A (en)	1996-10-04	1999-11-02	Loma Linda University	Construction and expression of renilla luciferase and green fluorescent protein fusion genes
ES2301183T3 (es)	1996-12-03	2008-06-16	Amgen Fremont Inc.	Anticuerpo completamente humano que se une al receptor del egfr.
JP3795533B2 (ja)	1996-12-12	2006-07-12	プロルーム・リミテツド	感染性物質を検出及び同定するための方法及び装置
US6245974B1 (en)	1997-08-06	2001-06-12	North Carolina State University	Matrix attachment regions
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
GB9806530D0 (en)	1998-03-26	1998-05-27	Glaxo Group Ltd	Inflammatory mediator
EP1064360B1 (en)	1998-03-27	2008-03-05	Prolume, Ltd.	Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics
US6177612B1 (en)	1998-07-31	2001-01-23	Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada	Matrix attachment regions
AU762382B2 (en)	1998-09-29	2003-06-26	Pioneer Hi-Bred International, Inc.	MAR/SAR elements flanking RSYN7-driven construct
US6833268B1 (en)	1999-06-10	2004-12-21	Abgenix, Inc.	Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CA2388063C (en)	1999-11-24	2010-06-08	Immunogen, Inc.	Cytotoxic agents comprising taxanes and their therapeutic use
US20030096339A1 (en)	2000-06-26	2003-05-22	Sprecher Cindy A.	Cytokine receptor zcytor17
KR100408844B1 (ko)	2000-07-29	2003-12-06	한국산업기술평가원	동물세포 발현벡터
US6333410B1 (en)	2000-08-18	2001-12-25	Immunogen, Inc.	Process for the preparation and purification of thiol-containing maytansinoids
WO2002048379A1 (en)	2000-12-15	2002-06-20	Pangen Biotech Inc.	Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta
JP4307079B2 (ja)	2001-01-26	2009-08-05	セレキスエスアー	マトリックス付着領域およびその使用方法
AU2002319402B2 (en)	2001-06-28	2008-09-11	Domantis Limited	Dual-specific ligand and its use
US7230167B2 (en)	2001-08-31	2007-06-12	Syngenta Participations Ag	Modified Cry3A toxins and nucleic acid sequences coding therefor
US7064186B2 (en)	2002-01-18	2006-06-20	Zymogenetics, Inc.	Cytokine zcytor17 ligand
EP1576112B1 (en)	2002-01-18	2012-02-29	ZymoGenetics, Inc.	Cytokine receptor zcytor17 multimers
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US20050276812A1 (en)	2004-06-01	2005-12-15	Genentech, Inc.	Antibody-drug conjugates and methods
AU2003244817B2 (en)	2002-06-28	2010-08-26	Domantis Limited	Antigen-binding immunoglobulin single variable domains and dual-specific constructs
DE60336149D1 (de)	2002-08-16	2011-04-07	Immunogen Inc	Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
AU2003290330A1 (en)	2002-12-27	2004-07-22	Domantis Limited	Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US7755007B2 (en)	2003-04-17	2010-07-13	K&H Manufacturing, Inc	Heated pet mat
JP2007510434A (ja)	2003-11-12	2007-04-26	シェーリング　コーポレイション	多重遺伝子発現のためのプラスミドシステム
US7235641B2 (en)	2003-12-22	2007-06-26	Micromet Ag	Bispecific antibodies
JP4803789B2 (ja) *	2004-02-03	2011-10-26	独立行政法人科学技術振興機構	疼痛を処置するための薬学的組成物
AU2005218642B2 (en)	2004-03-02	2011-04-28	Seagen Inc.	Partially loaded antibodies and methods of their conjugation
CA2562953A1 (en)	2004-03-30	2005-10-13	Glaxo Group Limited	Humanized and chimeric anti-osm antibodies
EP1817341A2 (en)	2004-11-29	2007-08-15	Seattle Genetics, Inc.	Engineered antibodies and immunoconjugates
US7301019B2 (en)	2005-01-21	2007-11-27	Immunogen, Inc.	Method for the preparation of maytansinoid esters
EP1846455A4 (en) *	2005-02-03	2010-02-17	Raven Biotechnologies Inc	ANTIBODY TO THE ONKOSTATIN M RECEPTOR
WO2006088855A1 (en)	2005-02-14	2006-08-24	Zymogenetics, Inc.	Methods of treating skin disorders using an il-31ra antagonist
US8101183B2 (en)	2005-05-06	2012-01-24	Zymogentics, Inc.	Variable region sequences of IL-31 monoclonal antibodies
BRPI0611069A2 (pt)	2005-05-06	2010-11-09	Zymogenetics Inc	anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
SG162788A1 (en)	2005-06-14	2010-07-29	Amgen Inc	Self-buffering protein formulations
NZ564843A (en)	2005-08-03	2012-05-25	Immunogen Inc	Immunoconjugate formulations comprising an immunoconjugate and an excipient in a buffered aqueous solution
EP1913002B9 (en)	2005-08-09	2012-04-25	Millennium Pharmaceuticals, Inc.	Method of acylating maytansinol with chiral amino acids
JP2009526756A (ja) *	2006-01-10	2009-07-23	ザイモジェネティクス，インコーポレイテッド	Ｉｌ−３１ｒａアンタゴニストおよびｏｓｍｒｂアンタゴニストを用いて神経組織における疼痛および炎症を治療する方法
CN101395920A (zh)	2006-03-01	2009-03-25	汤姆森特许公司	生成媒体包的设备与方法
UA100116C2 (ru)	2006-06-08	2012-11-26	Чугей Сейяку Кабусики Кайся	Профилактика или лечение воспалительного заболевания
KR101501660B1 (ko)	2006-09-01	2015-03-11	지모제넥틱스, 인코포레이티드	Ｉｌ―31 단클론 항체의 가변 영역 서열 및 사용 방법
EA200970477A1 (ru) *	2006-11-15	2009-12-30	Медарекс, Инк.	Человеческие моноклональные антитела к btla и способы применения
ES2381788T3 (es)	2007-07-16	2012-05-31	Genentech, Inc.	Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
US7695963B2 (en)	2007-09-24	2010-04-13	Cythera, Inc.	Methods for increasing definitive endoderm production
PT2796466T (pt)	2007-12-07	2018-02-23	Zymogenetics Inc	Moléculas de anticorpo humanizado específicas para il-31
EP3663318A1 (en)	2008-01-07	2020-06-10	Amgen Inc.	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
IL287292B (en)	2008-01-31	2022-09-01	Genentech Inc	and fusion antibody-drug-cd79b engineered antibodies cysteine-
BRPI0910746B8 (pt)	2008-04-30	2021-05-25	Immunogen Inc	agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica
CN102369291A (zh)	2009-01-23	2012-03-07	比奥根艾迪克Ma公司	效应子功能降低的稳定Fc多肽及使用方法
WO2013168829A1 (en) *	2012-05-11	2013-11-14	Wakayama Medical University	Anti oncostatin m receptor beta antibody
US9401875B2 (en)	2012-06-01	2016-07-26	Nippon Telegraph And Telephone Corporation	Packet transfer processing method and packet transfer processing device
US9663571B2 (en)	2013-05-30	2017-05-30	Kiniksa Pharmaceuticals, Ltd.	Oncostatin M receptor antigen binding proteins
US9550828B2 (en)	2013-09-05	2017-01-24	Boise State University	Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US9209965B2 (en)	2014-01-14	2015-12-08	Microsemi Semiconductor Ulc	Network interface with clock recovery module on line card
US9300829B2 (en)	2014-04-04	2016-03-29	Canon Kabushiki Kaisha	Image reading apparatus and correction method thereof

2014
- 2014-05-30 US US14/891,491 patent/US9663571B2/en active Active
- 2014-05-30 CN CN201480031080.5A patent/CN105555803B/zh active Active
- 2014-05-30 PT PT18185359T patent/PT3456743T/pt unknown
- 2014-05-30 EP EP18185359.9A patent/EP3456743B1/en active Active
- 2014-05-30 EA EA201592285A patent/EA201592285A1/ru unknown
- 2014-05-30 NZ NZ753995A patent/NZ753995A/en active IP Right Revival
- 2014-05-30 AU AU2014273966A patent/AU2014273966B2/en active Active
- 2014-05-30 KR KR1020157034312A patent/KR101882366B1/ko active IP Right Grant
- 2014-05-30 WO PCT/US2014/040360 patent/WO2014194274A2/en active Application Filing
- 2014-05-30 PL PL18185359T patent/PL3456743T3/pl unknown
- 2014-05-30 BR BR112015029643-2A patent/BR112015029643B1/pt active IP Right Grant
- 2014-05-30 SI SI201430916T patent/SI3004167T1/sl unknown
- 2014-05-30 KR KR1020187021007A patent/KR102258460B1/ko active IP Right Grant
- 2014-05-30 ES ES14734671.2T patent/ES2692657T3/es active Active
- 2014-05-30 TR TR2018/15608T patent/TR201815608T4/tr unknown
- 2014-05-30 HU HUE18185359A patent/HUE056580T2/hu unknown
- 2014-05-30 NZ NZ713636A patent/NZ713636A/en active IP Right Revival
- 2014-05-30 SI SI201431906T patent/SI3456743T1/sl unknown
- 2014-05-30 HU HUE14734671A patent/HUE040548T2/hu unknown
- 2014-05-30 CN CN201710655839.2A patent/CN107513105B/zh active Active
- 2014-05-30 EP EP23210981.9A patent/EP4349864A2/en active Pending
- 2014-05-30 DK DK18185359.9T patent/DK3456743T3/da active
- 2014-05-30 EP EP21190497.4A patent/EP3971212B1/en active Active
- 2014-05-30 SG SG11201508829QA patent/SG11201508829QA/en unknown
- 2014-05-30 EP EP14734671.2A patent/EP3004167B1/en active Active
- 2014-05-30 CA CA2910732A patent/CA2910732A1/en active Pending
- 2014-05-30 DK DK14734671.2T patent/DK3004167T3/en active
- 2014-05-30 JP JP2016517062A patent/JP6243521B2/ja active Active
- 2014-05-30 PL PL14734671T patent/PL3004167T3/pl unknown
- 2014-05-30 ES ES18185359T patent/ES2895824T3/es active Active
- 2014-05-30 PT PT14734671T patent/PT3004167T/pt unknown
- 2014-05-30 KR KR1020217015688A patent/KR102652165B1/ko active IP Right Grant
- 2014-05-30 MX MX2015016304A patent/MX351127B/es active IP Right Grant
- 2014-05-30 CN CN201910733125.8A patent/CN110511279B/zh active Active
2015
- 2015-10-30 ZA ZA2015/08064A patent/ZA201508064B/en unknown
- 2015-11-26 MX MX2020003503A patent/MX2020003503A/es unknown
2016
- 2016-08-24 HK HK16110088.4A patent/HK1221961A1/zh unknown
- 2016-09-28 US US15/279,305 patent/US9593163B2/en active Active
- 2016-11-01 HK HK16112538.6A patent/HK1224310A1/zh unknown
- 2016-11-01 HK HK18107986.1A patent/HK1249522A1/zh unknown
2017
- 2017-04-12 US US15/486,094 patent/US9738721B1/en active Active
- 2017-05-29 JP JP2017105838A patent/JP6606122B2/ja active Active
- 2017-07-11 US US15/646,699 patent/US10421813B2/en active Active
- 2017-09-15 AU AU2017228686A patent/AU2017228686B2/en active Active
2019
- 2019-06-16 IL IL267382A patent/IL267382B/en unknown
- 2019-08-07 US US16/534,900 patent/US20190359724A1/en not_active Abandoned
- 2019-10-17 JP JP2019189968A patent/JP2020022482A/ja active Pending
2020
- 2020-02-11 AU AU2020200980A patent/AU2020200980B2/en active Active
2021
- 2021-09-03 US US17/466,395 patent/US20220056144A1/en active Pending
- 2021-11-03 IL IL287824A patent/IL287824A/en unknown
2022
- 2022-04-14 AU AU2022202503A patent/AU2022202503A1/en active Pending
- 2022-09-27 JP JP2022153731A patent/JP7474817B2/ja active Active

Also Published As

Publication number	Publication date
EP3456743A1 (en)	2019-03-20
CN105555803A (zh)	2016-05-04
EP3456743B1 (en)	2021-08-18
BR112015029643B1 (pt)	2023-12-12
US10421813B2 (en)	2019-09-24
NZ753995A (en)	2022-07-01
CA2910732A1 (en)	2014-12-04
HK1249522A1 (zh)	2018-11-02
JP7474817B2 (ja)	2024-04-25
AU2017228686B2 (en)	2019-11-14
KR102652165B1 (ko)	2024-03-27
JP2020022482A (ja)	2020-02-13
BR112015029643A2 (pt)	2017-09-26
MX2015016304A (es)	2016-03-21
US20170218076A1 (en)	2017-08-03
WO2014194274A3 (en)	2015-03-12
KR20180086295A (ko)	2018-07-30
AU2014273966A1 (en)	2015-11-12
KR101882366B1 (ko)	2018-07-30
KR102258460B1 (ko)	2021-06-02
CN107513105B (zh)	2019-08-16
SI3456743T1 (sl)	2022-01-31
KR20210064400A (ko)	2021-06-02
JP2016520619A (ja)	2016-07-14
AU2017228686A1 (en)	2017-10-05
CN110511279B (zh)	2024-03-29
EP3971212B1 (en)	2023-12-27
EP3004167A2 (en)	2016-04-13
EP3004167B1 (en)	2018-07-25
US20220056144A1 (en)	2022-02-24
EP3971212A1 (en)	2022-03-23
JP2022180573A (ja)	2022-12-06
US20160137739A1 (en)	2016-05-19
CN110511279A (zh)	2019-11-29
JP6606122B2 (ja)	2019-11-13
PT3004167T (pt)	2018-11-13
MX2020003503A (es)	2020-07-22
US9663571B2 (en)	2017-05-30
AU2022202503A1 (en)	2022-05-12
US9593163B2 (en)	2017-03-14
EP3971212C0 (en)	2023-12-27
IL267382B (en)	2021-12-01
US20170008958A1 (en)	2017-01-12
ES2895824T3 (es)	2022-02-22
WO2014194274A2 (en)	2014-12-04
MX351127B (es)	2017-10-03
US20180002429A1 (en)	2018-01-04
DK3004167T3 (en)	2018-11-12
IL287824A (en)	2022-01-01
IL267382A (en)	2019-08-29
EA201592285A1 (ru)	2016-05-31
ZA201508064B (en)	2019-07-31
NZ713636A (en)	2022-07-01
DK3456743T3 (da)	2021-09-27
AU2014273966B2 (en)	2017-08-31
US20190359724A1 (en)	2019-11-28
HK1221961A1 (zh)	2017-06-16
EP4349864A2 (en)	2024-04-10
JP6243521B2 (ja)	2017-12-06
TR201815608T4 (tr)	2018-11-21
PL3004167T3 (pl)	2019-01-31
US9738721B1 (en)	2017-08-22
PL3456743T3 (pl)	2022-03-07
ES2692657T3 (es)	2018-12-04
SI3004167T1 (sl)	2019-01-31
CN107513105A (zh)	2017-12-26
KR20160011644A (ko)	2016-02-01
CN105555803B (zh)	2019-09-10
AU2020200980B2 (en)	2022-04-28
SG11201508829QA (en)	2015-12-30
AU2020200980A1 (en)	2020-02-27
HK1224310A1 (zh)	2017-08-18
PT3456743T (pt)	2021-10-27
JP2017140056A (ja)	2017-08-17
HUE056580T2 (hu)	2022-02-28

Publication	Publication Date	Title
IL287824A (en)	2022-01-01	Oncostatin m receptor antigen-binding proteins
IL282226A (en)	2021-05-31	ST2 antigen-binding proteins
HK1225641A1 (zh)	2017-09-15	Gitr抗原結合蛋白
IL240838A0 (en)	2015-10-29	Anti-3–lag binding proteins
HK1215592A1 (zh)	2016-09-02	蛋白偶聯受體庫